The Technical Analyst
Vigil Neuroscience, Inc. [VIGL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vigil Neuroscience, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.55% $2.82
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 104.01 mill |
| EPS: | -2.13 |
| P/E: | -1.320 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 36.88 mill |
| Avg Daily Volume: | 0.0893 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.320 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.22x |
| Company: PE -1.320 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.985 (-65.06%) $-1.835 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.50 - 3.14 ( +/- 11.21%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-18 | Kaufmann Petra | Buy | 330 000 | Stock Option Grant (Right to Buy) |
| 2024-03-18 | Kaufmann Petra | Buy | 0 | |
| 2024-03-01 | Booth Bruce | Buy | 34 612 | Stock Option Grant (Right to Buy) |
| 2024-03-01 | Bruhn Suzanne Louise | Buy | 24 073 | Stock Option Grant (Right to Buy) |
| 2024-03-01 | Blanchard Cheryl R | Buy | 24 761 | Stock Option Grant (Right to Buy) |
| INSIDER POWER |
|---|
| 99.98 |
| Last 93 transactions |
| Buy: 32 103 135 | Sell: 31 582 660 |
Forecast:
16:00 - $2.81
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.81
Forecast 2: 16:00 - $2.81
Forecast 3: 16:00 - $2.81
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.82 (2.55% ) |
| Volume | 0.0637 mill |
| Avg. Vol. | 0.0893 mill |
| % of Avg. Vol | 71.37 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VIGL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VIGL
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-17 16:05:00 - Press Release
Vigil Presents Key Findings From Illuminate & Ignite Studies In Alsp At The 2024 American Academy Of Neurology Annual Meeting
- findings from illuminate natural history study show that mri and fluid biomarkers are emerging as key measures of alsp pathophysiology -
2024-03-26 07:05:00 - Press Release
Vigil Neuroscience Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
– reported positive interim data from phase 2 ignite proof-of-concept clinical trial evaluating iluzanebart (vgl101) for treatment of alsp –
2024-03-20 07:05:00 - Press Release
Vigil Neuroscience Appoints Petra Kaufmann, M.d., As Chief Medical Officer
Watertown, mass., march 20, 2024 (globe newswire) -- vigil neuroscience, inc. (nasdaq: vigl), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of petra kaufmann, m.d., m.s., f.a.a.n, as chief medical officer. dr. kaufmann succeeds christopher j. silber, m.d.
2024-03-13 07:05:00 - Press Release
Vigil Announces Upcoming Presentations At 2024 American Academy Of Neurology Annual Meeting
Watertown, mass., march 13, 2024 (globe newswire) -- vigil neuroscience, inc. (nasdaq: vigl), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 american academy of neurology (aan) annual meeting taking place on april 13-18, 2024 in denver, colorado and virtually.
2024-03-12 07:05:00 - Press Release
Vigil Neuroscience To Present At Stifel 2024 Virtual Cns Days
Watertown, mass., march 12, 2024 (globe newswire) -- vigil neuroscience, inc. (nasdaq: vigl), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that ivana magovČeviĆ-liebisch, ph.d., j.d., president will participate in a fireside chat at the stifel 2024 virtual cns days on tuesday, march 19th at 3:30 p.m. e.t.
Latest News
2024-03-12 07:05:00 - GlobeNewsWire
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Tuesday, March 19th at 3:30 p.m. E.T.
2024-02-07 16:05:00 - GlobeNewsWire
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, at 1:30 p.m. E.T.
2023-11-22 16:05:00 - GlobeNewsWire
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, at 3:50 p.m. E.T.
2023-11-20 19:34:03 - Seeking Alpha
Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway
Positive interim results reported from phase 2 IGNITE study using iluzanebart for ALSP treatment from 6 patients. Additional results from phase 2 IGNITE study usung iluzanebart for the treatment of patients with ALSP from both 20 mg and 40 mg doses expected Q3 of 2024. Data from IGNITE study and ILLUMINATE study are going to be discussed with the FDA so that the company can possibly obtain Accelerated Approval pathway of iluzanebart for ALSP.
2023-10-05 16:01:00 - GlobeNewsWire
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 1:30 p.m. ET.
2023-09-18 14:38:55 - Seeking Alpha
Vigil Neuroscience: Interesting Early Data, Wait For Phase 2
Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial function. Their lead candidate, VGL101, is a monoclonal antibody agonist of TREM2, a microglial receptor protein involved in regulating microglial activation and phagocytosis. VGL101 has shown favorable safety and tolerability in phase 1 trials, with proof-of-target engagement and pharmacologic activity. Phase 2 data is expected in Q4.
2023-09-08 07:05:00 - GlobeNewsWire
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2023 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 11, 2023, at 9:20 a.m. ET.
2023-06-01 07:00:00 - GlobeNewsWire
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2023 Jefferies Global Healthcare Conference in New York City on Thursday, June 8, 2023, at 9:00 a.m. ET.
2023-03-22 07:00:00 - GlobeNewsWire
Vigil Neuroscience to Present at Stifel 2023 CNS Days
WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 CNS Days virtual conference on Wednesday, March 29, 2023, at 12:00 p.m. ET.
2023-01-03 07:00:00 - GlobeNewsWire
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 8:15 a.m. PT / 11:15 a.m. ET.